Thailand Peptides
Get in Contact
Catalog
PeptidesCategories
Research
CompareInformation
Calculator
Get in Contact
Comparison · Cognitive & Nootropic

Cerebrolysin vs Semax

Cerebrolysin and Semax both appear in stroke-recovery research, but they are very different tools. Cerebrolysin is a porcine-derived peptide mixture with neurotrophic activity and clinical registration for stroke and dementia in Europe and Asia. Semax is a synthetic heptapeptide with BDNF-elevating activity.

Bangkok research desk ·

Side-by-side

Cerebrolysin Semax
MechanismPorcine-derived peptide mixture; neurotrophic factor-like activity.ACTH(4-10) analog; BDNF and NGF elevation; monoaminergic modulation.
Half-lifeAdministered as a course.Short (intranasal).
Dose5-30 mL IM or IV.250-500 mcg × 2-3 daily intranasal.
CycleDaily for 10-20 days; 2 courses/year typical.14 days on / 14 off.
Research contextCARS and CASTA trials: stroke recovery; registered for stroke and dementia1.Russian registration for stroke and ADHD; BDNF/NGF mechanism2.
Cost tierHigh (IV/IM administration, large volume).Low-to-mid.

Cerebrolysin and Semax operate on different scales. Cerebrolysin is a complex peptide preparation derived from porcine brain tissue, administered as a multi-mL IV or IM infusion course1. Its mechanism is characterised as neurotrophic-factor-like, mimicking aspects of BDNF, NGF, and other endogenous growth factors. It is registered in Europe, Asia, and parts of Latin America for stroke recovery and dementia indications.

Semax is a single synthetic heptapeptide, administered as an intranasal spray at microgram doses2. Its mechanism is narrower: BDNF and NGF elevation plus monoaminergic modulation. It is registered in Russia for stroke recovery and attention-related indications, and used more often in maintenance/self-research contexts than acute clinical ones.

Research-protocol fit diverges sharply. Cerebrolysin research protocols are course-based, clinical-grade, and typically run in acute stroke or dementia populations with the full monitoring that implies. Semax research protocols are lighter-touch, intranasal, and typically run in cognitive-enhancement or attention contexts rather than acute clinical ones. The two are rarely compared as substitutes; they are compared because both appear in the stroke-recovery literature, but the research design and administration context are quite different. See nootropic peptide mechanisms for the broader class map.

Frequently asked

Is Cerebrolysin clinically registered?
Yes, in Europe, Asia, and parts of Latin America. It has large clinical trials in stroke recovery (CARS, CASTA) and dementia1. Not registered in the US.
Can Semax substitute for Cerebrolysin?
Not clinically. The compounds are different in scale, mechanism breadth, and administration route. Cerebrolysin is a clinical-grade infusion course; Semax is an intranasal research peptide.
What does a Cerebrolysin course look like?
5-30 mL daily IV or IM for 10-20 days, typically repeated 1-2 times per year. The large volume and clinical-grade administration is what distinguishes it from short peptide nootropics.
Research desk
Ordering both Cerebrolysin and Semax for a research protocol? The Bangkok desk handles pricing, COA, and timing on WhatsApp.
Open a line with the research desk ≥98% HPLC purity · supplier COA on file · Bangkok-based

Go deeper

Related comparisons

References

  1. Muresanu DF, et al. Cerebrolysin and Recovery After Stroke (CARS): A Randomized, Placebo-Controlled, Double-Blind Trial. Stroke. 2016. PMID: 26564102
  2. Dolotov OV, et al. Semax, an analogue of ACTH(4-10), binds specifically and increases BDNF. J Neurochem. 2006. PMID: 16635254

All references verified against PubMed via NCBI E-utilities.